Biostar Technologies
Beijing Biostar Pharmaceuticals (2563.HK) is a Chinese biopharmaceutical company that develops novel anti-tumor drugs via proprietary synthetic biology platforms, with its lead product Utidelone injection approved in China for advanced breast cancer and a 19-project pipeline targeting breast cancer brain metastases, gastric, pancreatic, lung, and ovarian cancers.
- Company typePublic
- Founded2002
- HeadquartersBeijing, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Biostar Technologies firmographics
Firmographics- Name
- Biostar Technologies
- Legal name
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Website
- https://biostar-pharm.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Beijing Biostar Pharmaceuticals (2563.HK) is a Chinese biopharmaceutical company that develops novel anti-tumor drugs via proprietary synthetic biology platforms, with its lead product Utidelone injection approved in China for advanced breast cancer and a 19-project pipeline targeting breast cancer brain metastases, gastric, pancreatic, lung, and ovarian cancers.
- Ownership category
- akta.pro rank
Biostar Technologies industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Biostar Technologies is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Biostar Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Utidelone Injection Sales: Sales of Utidelone injection (brand name: 优替帝), a Class 1 innovative drug approved by NMPA in March 2021 for treatment of advanced and metastatic breast cancer. Listed in 2022 National Medical Insurance Drug Catalog.
- Regional Licensing and Co-development: Out-licensing and co-development deals for Utidelone injection and capsule in international markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Utidelone Injection (优替帝) - Listed in National Medical Insurance Drug Catalog |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Biostar Technologies product offering
Product offeringCore offering
Biostar Technologies develops and commercializes innovative anti-tumor drugs built on proprietary synthetic biology platforms, with one NMPA-approved commercial product — Utidelone injection (优替帝) for advanced breast cancer — and 19 pipeline projects across NSCLC, ovarian, gastric, pancreatic, and other solid tumor indications. The company manufactures its drugs through microbial fermentation at its Chengdu facility, distributes them in China via Baheal Medical, and out-licenses regional rights to global pharmaceutical partners.
Product overview
Biostar Technologies is a computer hardware manufacturer offering a diverse portfolio of products including industrial motherboards and fanless IPC systems for AIoT and edge computing applications, consumer motherboards for gaming and productivity builds, graphics cards, and memory/storage solutions. The company has recently expanded into AI computing with NVIDIA Jetson Orin-based edge solutions and collaborative AI products developed with partners DEEPX and MemryX.
Differentiator
Problem solved
Functional benefit
Brands
- 优替帝 (Utide): Brand name for Utidelone injection product
- Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd.
Products and services
- Utidelone injection (优替帝) Utidelone injection is a novel microtubule stabilizer (epothilone analog) NMPA-approved for advanced/metastatic breast cancer, including patients who have failed taxane-based chemotherapy and those with brain metastases. It is administered to oncology patients in Chinese hospitals and distributed exclusively through Baheal Medical.
- Utidelone oral capsule Oral capsule formulation of Utidelone being developed as a non-infusion alternative to the injectable product for advanced breast cancer and other solid tumor indications, currently in Phase III clinical development.
- ADC (Antibody-Drug Conjugate) Platform Candidates ADC pipeline products leveraging the company's epothilone payload chemistry and synthetic biology platform to develop targeted antibody-drug conjugates for solid tumors.
- Utidelone new indication pipeline (NSCLC, ovarian, pancreatic, gastric cancers) Pipeline program extending the approved Utidelone microtubule stabilizer into additional oncology indications — NSCLC, ovarian cancer, pancreatic cancer, and gastric cancer — including orphan drug designations in pancreatic and gastric cancers.
Quantifiable outcome
- Phase III trial: significantly improved progression-free survival and overall survival vs standard regimens in advanced breast cancer
- +5 more outcomes
Companies that use Biostar Technologies
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Biostar Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biostar Technologies partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Baheal Medical (百洋医药)coreBaheal Medical invested approximately 1 billion HKD through subscription of 25 million new shares, acquiring 7.49% stake. Holds exclusive marketing rights for Utidelone injection in mainland China. IPO cornerstone investor and strategic partner.
- MD Anderson Cancer CentercoreParticipating institution in UTD1 plus capecitabine pivotal US clinical trial for HER2-negative breast cancer brain metastases (NCT06764940)
- John Hopkins Sidney Kimmel Comprehensive Cancer CentercoreParticipating institution in UTD1 plus capecitabine pivotal US clinical trial for HER2-negative breast cancer brain metastases
- City of Hope-Duarte Cancer CentercoreParticipating institution in US pivotal clinical trial for breast cancer brain metastases
- Northwestern University Robert H. Lurie Comprehensive Cancer CentercoreParticipating institution in US pivotal clinical trial for breast cancer brain metastases
- UT Southwestern Medical CentercoreUS clinical trial site for BG02-2404 study (UTD2 gastric cancer international multi-regional Phase II/III trial)
- US Clinical Trial Network (20 cancer centers)minorApproximately 20 US oncology centers participating in pivotal clinical trials for breast cancer brain metastases indication
- Global Business Development PartnerscoreActively seeking global partners for out-licensing or co-development of Utidelone injection and capsule. Contact via [email protected].
Scale indicators4 records
Recent moves11 records
Expansion highlights6 records
Biostar Technologies competitors and assessment
Company assessmentDirect peers
- Cstone Pharmaceuticals: HKEX-listed Chinese innovative oncology biotech with a similar profile of one or more commercialized/novel oncology assets and a heavy pipeline focus. Comparable as a peer-stage Chinese oncology drug developer using novel mechanisms and indication expansion strategies.
- Hutchmed (China MediTech): HKEX- and NASDAQ-listed Chinese oncology biotech commercializing novel targeted therapies through global development and out-licensing. Comparable to Biostar in pursuing a China-rooted novel-mechanism oncology franchise with international licensing as the growth lever.
- Akeso, Inc. Hong Kong-listed Chinese biotech focused on novel oncology antibodies and bispecifics. Comparable to Biostar as a similarly staged HKEX-listed Chinese innovator driving a differentiated oncology pipeline.
- RemeGen Co., Ltd. HKEX-listed Chinese biotech commercializing innovative biologics in oncology. Comparable as a peer in stage, listing venue, and focus on novel oncology biologics from a domestic innovation platform.
- Shanghai Junshi Biosciences: HKEX-listed Chinese biotech commercializing innovative oncology biologics including immuno-oncology therapies. Comparable as a peer-stage Chinese oncology innovator with similar global development ambitions.
Broad incumbents
- Innovent Biologics: Established HKEX-listed Chinese biotech with multiple commercial oncology assets including PD-1 inhibitors. Comparable as a broader incumbent in Chinese innovative oncology, though larger and more diversified than Biostar's single-asset focus.
- BeiGene: Global Chinese oncology company with commercialized BTK and PD-1 inhibitors. Comparable as a broader oncology incumbent, but operates at materially larger scale and global commercial footprint.
- Hansoh Pharmaceutical Group: Large HKEX-listed Chinese pharmaceutical company with multiple oncology and CNS drugs. Comparable as a broader incumbent in oncology innovative drugs, though operating at substantially greater commercial scale.
- Bristol-Myers Squibb: Global oncology incumbent with the established taxane franchise (paclitaxel, nab-paclitaxel, cabazitaxel) that competes directly with Utidelone's microtubule stabilization mechanism. Comparable as the dominant incumbent in the microtubule stabilizer category.
- Shanghai Fosun Pharmaceutical: Major Chinese pharmaceutical group with established oncology portfolio and licensing partnerships. Comparable as a broader incumbent actively pursuing innovative oncology assets and global licensing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Biostar Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biostar Technologies leadership team
Management profileNumber of profiles
Profiles11 records
Biostar Technologies subsidiaries and ownership
Company hierarchySubsidiaries2 records
Biostar Technologies funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biostar Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biostar Technologies
What does Biostar Technologies do?
Biostar Technologies develops and commercializes innovative anti-tumor drugs built on proprietary synthetic biology platforms, with one NMPA-approved commercial product — Utidelone injection (优替帝) for advanced breast cancer — and 19 pipeline projects across NSCLC, ovarian, gastric, pancreatic, and other solid tumor indications. The company manufactures its drugs through microbial fermentation at its Chengdu facility, distributes them in China via Baheal Medical, and out-licenses regional rights to global pharmaceutical partners.
Is Biostar Technologies a public or private company?
Biostar Technologies is a public company. It is classified as public and is currently operating.
When was Biostar Technologies founded?
Biostar Technologies was founded in 2002. It employs 101 to 250 people.
Where is Biostar Technologies based?
Biostar Technologies is headquartered in Beijing, China, in the Asia region.
How does Biostar Technologies make money?
Two revenue lines are on record. Utidelone Injection Sales are the primary driver. The others are regional Licensing and Co-development.
Who are Biostar Technologies's main competitors?
Direct peers on record are Cstone Pharmaceuticals, Hutchmed (China MediTech), Akeso, Inc., RemeGen Co., Ltd. and Shanghai Junshi Biosciences. Broad incumbents are Innovent Biologics, BeiGene, Hansoh Pharmaceutical Group, Bristol-Myers Squibb and Shanghai Fosun Pharmaceutical.
Does Biostar Technologies have an API?
No public API is recorded for Biostar Technologies.
What industry is Biostar Technologies in?
Biostar Technologies's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.